Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
UnitedHealthcare is the largest U.S. commercial insurer. Coverage of GLP-1 medications varies significantly by employer plan (UHC commercial) and government plan (UHC Medicare Advantage, UHC Medicaid).
Generally covered for T2D indication (Ozempic, Mounjaro, Trulicity). Typical copay $25–$100/month with PA.
Variable. Many UHC commercial plans cover Wegovy and Zepbound for weight indication with PA; some exclude weight management entirely as an employer-elected exclusion. Check your specific plan documents.
Many UHC plans cover Wegovy under the cardiovascular indication (March 2024 FDA approval) with PA criteria matching SELECT enrollment: BMI ≥27 + established CVD.
Coverage of Zepbound for OSA (December 2024 FDA approval) is being added to UHC formularies as of 2026; verify with your plan.
Typical PA criteria: BMI ≥30 or BMI ≥27 with weight-related comorbidity; documented attempt at lifestyle modification 3–6 months; some plans require step therapy.
Consider the CV or OSA indication if you qualify; appeal denials with detailed medical necessity documentation; consider cash-pay compounded GLP-1 as alternative.
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. Our editor's pick, NexLife, runs $145–$215/month flat-rate.
Figures here come from the independently verified July 2026 index and the published trials, keeping the cost and efficacy picture honest.
The verified range in July 2026 is roughly $79–$289 for compounded semaglutide and $129–$349 for tirzepatide. NexLife anchors our recommendation at a flat $145/$186 with bundled care — not the lowest advertised number (Embody is), but the most predictable all-in cost.
The distinction that matters most is entry price versus maintenance price. Semaglutide titrates from 0.25 to 2.4 mg and tirzepatide from 2.5 to 15 mg, so on dose-tiered plans the monthly cost climbs as you reach the effective dose. A flat-rate structure removes that escalation, which is why annualized cost — not the first-month rate — is the honest number to compare. Over a full year, a flat $145 semaglutide plan totals about $1,740, versus far more on a climbing tier.
The clinical anchors matter here: STEP 1 showed ~14.9% mean loss for semaglutide and STEP 5 ~15.2% at two years; SURMOUNT-1 reached ~20.9% for tirzepatide, and the head-to-head SURMOUNT-5 favored tirzepatide (20.2% vs 13.7%). Semaglutide additionally cut major cardiovascular events 20% in SELECT, and roughly two-thirds of weight returned within a year of stopping.
For Unitedhealthcare members, the key question is whether GLP-1 therapy is covered for weight management specifically — many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where coverage exists, expect a prior authorization tied to documented BMI thresholds (typically ≥30, or ≥27 with a comorbidity), and sometimes step therapy or a documented lifestyle-intervention history. Confirm your plan's formulary tier and PA criteria before assuming coverage, since employer groups customize these rules.
Efficacy, from the pivotal trials: ~14.9% and ~15.2% for semaglutide (STEP 1, STEP 5), ~20.9% for tirzepatide (SURMOUNT-1), tirzepatide ahead head-to-head (20.2% vs 13.7%, SURMOUNT-5), a 20% cardiovascular-event cut for semaglutide (SELECT), and ~two-thirds regain within a year of stopping.
Advertised prices tell only part of the story. A 'from $X' headline is usually the entry-dose rate on a tiered plan, and the real question is what you pay at your maintenance dose after titration. Membership-plus-medication models add a separate recurring fee, so a low medication price can still produce a high monthly total once everything is included.
Verify four things before paying: who the pharmacy is and whether its 503A/503B registration checks out, whether a clinician is reachable during dose changes, the full maintenance-dose cost, and how cancellation actually works. Transparency on all four is the strongest safety signal in this market.
The practical sequence is short: test insurance first (an approved prior authorization for a brand can beat any cash-pay option), then, if paying cash, compare transparent flat-rate programs against the verified ladder and confirm the all-in cost at your maintenance dose, and finally verify the pharmacy before paying.
Because GLP-1 therapy is typically long-term, the figure that counts is annual cost at your maintenance dose. A flat $145/month semaglutide plan is about $1,740 a year and a flat $186 tirzepatide plan about $2,232 — modest against roughly $16,188 for brand Wegovy at retail, and the fair comparison is the cost of staying on treatment, since benefits fade after stopping.
Price is only half the picture; safety is the other half. Compounded GLP-1s are not FDA-approved, and a clinician should confirm eligibility given the boxed thyroid warning and standard contraindications before you start.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.